Results from the Phase 2 clinical trial of FORTITUDE-ALS have recently been made available. Here is the update from MND Australia. "The trial failed to meet either of its primary or secondary endpoints, with the trial finding the following:

  • no statistical significance demonstrated for change in slow vital capacity (SVC) from baseline following 12 weeks of dosing; and
  • dose-response analyses for the secondary endpoint failed to demonstrate statistical significance between reldesemtiv and the placebo arms.

Congratulations and a very big thank you to Alli Young and everyone that assisted in organising a Trivia Night held recently at the Hunter Belle Cheese Cafe in Muswellbrook. The event was a great success raising $5,240 in support of this year's Walk to d'Feet MND Hunter. Pictured is the fantastic support crew from the event! 

We will kick off MND Week this year with the Illawarra Walk to d'Feet MND at Bulli on Sunday 5 May, then lots of sites across the week. 

We are very excited to announce MND NSW and MND Australia will have a combined team in this year's City2Surf. We have limited spots available for the Charity Superstar entries. As a Charity Superstar you will receive free entry to the City2Surf, a starting position in front of the pack, merchandise and lots more. Commit to raising $1,000 today and join us for the 2019 City2Surf. Visit

Subscribe to news and updates